Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kura Oncology, Inc.KURA · Entity 4871 | Chief Scientific Officer | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kura Oncology, Inc.
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,053 |
Reported balance
After 2026-09-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-24 · Exercise / conversion · Acquired 30,000 · Balance 63,053 F1: Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability. F2: Includes 629 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 42,327 |
Reported balance
After 2026-09-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-24 · Sale · Disposed 20,726 · Balance 42,327 F3: This transaction was executed in multiple trades at prices ranging from $10.82 to $10.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2027-01-22 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-24 · Exercise / conversion · Disposed 30,000 · Balance 0 F4: This option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability.
F2: Includes 629 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.
F3: This transaction was executed in multiple trades at prices ranging from $10.82 to $10.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001193125-26-402815 · ownership.xml · derivative · entry 3 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 30,000 shares Expires 2027-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 20,726 | $10.83 | $224,514.40 |
DisclosureSEC source: 0001193125-26-402815 · ownership.xml · nonDerivative · entry 2 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,327 F3 · price: This transaction was executed in multiple trades at prices ranging from $10.82 to $10.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 30,000 | $6.15 | $184,500.00 |
DisclosureSEC source: 0001193125-26-402815 · ownership.xml · nonDerivative · entry 1 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability. F2 · balance_after: Includes 629 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 27, 2026 Filed Jan 27, 2026 21:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,311 | $8.46 | $11,091.98 |
DisclosureSEC source: 0001193125-26-025306 · ownership.xml · nonDerivative · entry 1 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,424 F1 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 185,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004566 · ownership.xml · derivative · entry 1 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 16:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001193125-25-326948 · ownership.xml · derivative · entry 3 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 35,000 shares Expires 2026-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 16:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 23,726 | $9.78 | $231,931.14 |
DisclosureSEC source: 0001193125-25-326948 · ownership.xml · nonDerivative · entry 2 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,735 F3 · price: This transaction was executed in multiple trades at prices ranging from $9.77 to $9.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 16:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 35,000 | $4.80 | $168,000.00 |
DisclosureSEC source: 0001193125-25-326948 · ownership.xml · nonDerivative · entry 1 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability. F2 · balance_after: Includes 857 shares acquired on May 17, 2025 and 899 shares acquired on November 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 28, 2025 Filed Jan 28, 2025 20:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,320 | $7.87 | $10,390.91 |
DisclosureSEC source: 0000950170-25-010117 · ownership.xml · nonDerivative · entry 2 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,705 F2 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 28, 2025 Filed Jan 28, 2025 20:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 846 | $7.87 | $6,659.63 |
DisclosureSEC source: 0000950170-25-010117 · ownership.xml · nonDerivative · entry 1 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,025 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/21. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 17:32 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 185,000 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001415889-25-001045 · form4-01072025_100138.xml · derivative · entry 1 Burrows Francis · CIK 0002051119 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.